Optimal Value of CA19-9 Determined by KRAS-Mutated Circulating Tumor DNA Contributes to the Prediction of Prognosis in Pancreatic Cancer Patients
| Autor: | Hideki Ishikawa, Toshiki Rikiyama, Nao Kakizawa, Fumio Konishi, Iku Abe, Yuhei Endo, Hiroshi Noda, Yuji Takayama, Sawako Tamaki, Masaaki Saito, Koichi Suzuki, Kazushige Futsuhara, Fumiaki Watanabe |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Multivariate analysis CA-19-9 Antigen endocrine system diseases medicine.medical_treatment Science medicine.disease_cause Gastroenterology Article Circulating Tumor DNA Proto-Oncogene Proteins p21(ras) Medical research Internal medicine Pancreatic cancer Medicine Cutoff Humans Risk factor Aged Cancer Chemotherapy Multidisciplinary Receiver operating characteristic business.industry medicine.disease Prognosis Survival Analysis digestive system diseases Carcinoma Ductal Pancreatic Neoplasms Oncology Risk factors Lymphatic Metastasis Mutation CA19-9 Female KRAS Neoplasm Recurrence Local business |
| Zdroj: | Scientific Reports Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) |
| Popis: | Despite the acceptance of carbohydrate antigen 19-9 (CA19-9) as a valuable predictor for the prognosis of pancreatic ductal adenocarcinoma (PDAC), its cutoff value remains controversial. Our previous study showed a significant correlation between CA19-9 levels and the presence of KRAS-mutated ctDNA in the blood of patients with PDAC. Based on this correlation, we investigated the optimal cutoff value of CA19-9 before surgery. Continuous CA19-9 values and KRAS-mutated ctDNAs were monitored in 22 patients with unresectable PDAC who underwent chemotherapy between 2015 and 2017. Receiver operating characteristic curve analysis identified 949.7 U/mL of CA19-9 as the cutoff value corresponding to the presence of KRAS-mutated ctDNA. The median value of CA19-9 was 221.1 U/mL. Subsequently, these values were verified for their prognostic values of recurrence-free survival (RFS) and overall survival (OS) in 60 patients who underwent surgery between 2005 and 2013. Multivariate analysis revealed that 949.7 U/mL of CA19-9 was an independent risk factor for OS and RFS in these patients (P = 0.001 and P = 0.010, respectively), along with lymph node metastasis (P = 0.008 and P = 0.017), unlike the median CA19-9 level (P = 0.150 and P = 0.210). The optimal CA19-9 level contributes to the prediction of prognosis in patients with PDAC before surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|